<?xml version='1.0' encoding='utf-8'?>
<section article="ghg" article_name="Health - General" number="21-2A-06.1" title_number="21" title_name="Food, Drugs, and Cosmetics" subtitle_number="2A" subtitle_name="Prescription Drug Monitoring Program">
  <level label="a">
    <text>Naloxone medication data:</text>
    <level label="1">
      <text>Are confidential and privileged, and not subject to discovery, subpoena, or other means of legal compulsion in civil litigation;</text>
    </level>
    <level label="2">
      <text>Are not public records; and</text>
    </level>
    <level label="3">
      <text>Except as provided in subsection (b) of this section or as otherwise by law, may not be disclosed to any person.</text>
    </level>
  </level>
  <level label="b">
    <level label="1">
      <text>The Program shall disclose naloxone medication data, in accordance with regulations adopted by the Secretary, for public health surveillance, research, analysis, public reporting, and education after redaction of all information that could identify a patient, prescriber, dispenser, or any other individual.</text>
    </level>
    <level label="2">
      <text>The Secretary may require submission of an abstract explaining the scope and purpose of the research, analysis, public reporting, or education before disclosing naloxone medication data under paragraph (1) of this subsection.</text>
    </level>
  </level>
</section>
